Amia Capital LLP Myovant Sciences Ltd. Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$13.8 - $27.62 $346,531 - $693,565	-25,111 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $27,523 - $44,273	-1,959 Reduced 7.24%	25,111 $353,000
Q2 2020 Aug 14, 2020	SELL	$7.34 - $20.84 $109,366 - $310,516	-14,900 Reduced 35.5%	27,070 $558,000
Q1 2020 May 15, 2020	SELL	$6.55 - $14.76 $75,573 - $170,300	-11,538 Reduced 21.56%	41,970 $317,000
Q4 2019 Feb 13, 2020	BUY	$4.2 - $19.21 $224,733 - $1.03 Million	53,508 New	53,508 $830,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.